Immunological Effects of Interferon-alpha on Chronic Myelogenous Leukemia

• Published in: Leukemia & lymphoma 2003-12, Vol.44 (12), p.2061-2067
• Main Authors: de Castro, Fabiola Attié, Palma, Patricia Vianna Bonini, Morais, Fabiana Rossetto, Simões, Belinda Pinto, Carvalho, Paulo Villas-Boas, Ismael, Sebastião José, Voltarelli, Carmen Passos, Morais, Júlio César
• Format: Article
• Language: English
• Subjects: Adult; Antigens, CD34 - biosynthesis; Apoptosis; Chronic myelogenous leukemia; Cytokines - biosynthesis; Cytokines - metabolism; Cytokines and NK cytotoxicity; Female; Flow Cytometry; Humans; Immunophenotype; Immunophenotyping; Interferon-alpha - therapeutic use; Interferon-gamma - blood; Interferon-α; Interleukin-2 - blood; Interleukin-4 - blood; Killer Cells, Natural - immunology; Killer Cells, Natural - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Leukocytes, Mononuclear - metabolism; Male; Middle Aged; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; STAT3; Stem Cells - immunology; Time Factors
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/1042819031000110973

Treatment with interferon-α is effective for chronic myelogenous leukemia in the chronic phase (CML-CP), but the immunological mechanisms of the antileukemic effect of this substance are still unclear. The objective of this study was to investigate the immunological effects of interferon-α in CML patients. Markers of cellular activation and apoptosis, natural killer (NK) cell cytotoxicity and production of intracellular cytokines (IFN-γ, IL-2 and IL-4) were determined by flow cytometry in the peripheral blood mononuclear cells (PBMC) of 26 CML-CP patients before and 3, 6 and 9 months after IFN-α treatment. The results were correlated with the hematological response. In the whole group of patients, IFN-α use was followed by a significant increase of lymphocytes producing IL-2 and IFN-γ, an increase in NK activity and a decrease in the number of CD34+ cells. Out of 26 CML patients, 15 achieved hematological remission and 7 achieved partial cytogenetic remission after 9 months of IFN-α treatment. There was an increase in the percentage of CD8/FasL+, DR/CD3+, DQ/CD3+, CD34/Fas+, DR/CD56+, CD56/FasL+ cells and of IFN-γ- and IL-2-producing lymphocytes and an increase in NK cytotoxicity only in the group of patients who achieved complete hematological remission. Our results indicate that IFN-α use in CML-CP reduces the number of CD34+ cells, activates T cells, enhances stem cell apoptotic markers and increases the production of intracellular IFN-γ and IL-2 by lymphocytes. Taken together, these results indicate that the therapeutic effect of IFN-α in CML-CP is mediated at least in part by immunological mechanisms.